GlassScriptPhysician profile
Susan B Ward
NPI 1942208418
$1,688.56
in general payments reported to CMS, 2019-2025
24 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $75.03 · 2021: $320 · 2022: $183 · 2023: $417 · 2024: $87.34 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $488.54 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Lilly USA, LLC | $373.61 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Abbvie INC. | $157.34 | 2020-2025 | Skyrizi, Rinvoq |
| Radius Health, INC. | $139.58 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $56.67 | 2019 | |
| Ucb, INC. | $55.06 | 2019-2022 | |
| Horizon Therapeutics Plc | $48.48 | 2020-2022 | |
| Pfizer INC. | $46.03 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $41.34 | 2021 | |
| Janssen Biotech, INC. | $39.14 | 2019-2023 | Tremfya |
| Genzyme Corporation | $30.93 | 2019-2025 | |
| Madrigal Pharmaceuticals | $21.17 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $20.53 | 2024 | Orencia |
| Ani Pharmaceuticals, INC. | $18.43 | 2023 | Purified Cortrophin Gel |
| Mylan Institutional INC. | $18.32 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $16.80 | 2024 | Arcalyst |
| Kyowa Kirin, INC. | $16.78 | 2023 | Crysvita |
| Amneal Pharmaceuticals LLC | $15.83 | 2023 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.59 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $15.02 | 2020 | |
| W. L. Gore & Associates, INC. | $14.00 | 2021 | |
| Preventice Services, LLC | $13.96 | 2021 | |
| Genentech USA, INC. | $12.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.